THERIVA BIOLOGICS INC (TOVX)
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
$0.250.00%
Close 2026-09-04 · 1-day change
NYSE MKTHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TOVX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 5.3 | 8.6 | 12.0 | 14.3 | 11.7 | 7.8 | 5.1 | 11.1 | 11.8 | 18.8 | 29.1 | 32.9 | 14.5 | 6.5 | 12.3 | 3.3 |
| Operating Income | (11.9) | (24.1) | (26.3) | (21.4) | (21.6) | (14.3) | (10.2) | (15.7) | (17.6) | (26.3) | (39.3) | (41.0) | (20.5) | (12.3) | (17.3) | (5.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest & Investment Income | 0.3 | 0.3 | 0.7 | 1.4 | 0.5 | 0.0 | 0.0 | 0.3 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Other Non-Operating Income / Expenses | 0.3 | 0.3 | 0.7 | 1.4 | 0.5 | 0.0 | 0.0 | 0.3 | 4.2 | 10.8 | 11.4 | (3.8) | 0.7 | 0.0 | 0.0 | (1.7) |
| Asset Writedown | — | — | — | 0.0 | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | (11.6) | (23.7) | (25.7) | (20.0) | (21.1) | (14.3) | — | — | — | — | — | — | — | (12.3) | (17.3) | (5.9) |
| Income Tax Expense | — | — | 0.0 | (1.6) | (1.4) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | 0.0 | (0.0) | (0.1) | (0.1) | (0.1) | (0.3) | (0.5) | (1.0) | 0.0 | (0.0) | — | — |
| Net Income | — | (23.7) | (25.7) | (18.3) | (19.7) | (14.3) | (10.0) | (15.3) | (13.4) | (15.2) | (27.3) | (43.7) | (19.8) | (12.3) | (17.1) | (8.1) |
| Per Share | ||||||||||||||||
| Basic EPS | — | (2.08) | (19.03) | (28.48) | (1.31) | (1.90) | (0.66) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | — | (2.08) | (19.03) | (28.48) | (1.31) | (1.90) | (0.66) | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 45.9 | 12.1 | 1.3 | 0.6 | 15.3 | 12.2 | 19.0 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 45.9 | 12.1 | 1.3 | 0.6 | 15.3 | 12.2 | 19.0 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (23.9) | (26.2) | (21.3) | (21.5) | (14.2) | (10.0) | (15.4) | (17.3) | (26.0) | (39.1) | (40.9) | — | — | — | — |
| EBIT | (11.9) | (24.1) | (26.3) | (21.4) | (21.6) | (14.3) | (10.2) | (15.7) | (17.6) | (26.3) | (39.3) | (41.0) | (20.5) | (12.3) | (17.3) | (5.9) |
| Effective Tax Rate | — | — | — | 8.2% | 6.8% | 0.0% | — | — | — | — | — | — | — | 0.0% | 0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.